Weight gain is a common consequence of treatment with antipsychotic drugs in early psychosis, leading to further morbidity and poor treatment adherence. Identifying tools that can predict weight change in early psychosis may contribute to better-individualised treatment and adherence. Recently we showed that proteomic profiling with sequential window acquisition of all theoretical fragment ion spectra (SWATH) mass spectrometry (MS) can identify individuals with pre-diabetes more likely to experience weight change in relation to lifestyle change. We investigated whether baseline proteomic profiles predicted weight change over time using data from the BeneMin clinical trial of the anti-inflammatory antibiotic, minocycline, versus placebo. Expression levels for 844 proteins were determined by SWATH proteomics in 83 people (60 men and 23 women). Hierarchical clustering analysis and principal component analysis of baseline proteomics data did not reveal distinct separation between the proteome profiles of participants in different weight change categories. However, individuals with the highest weight loss had higher Positive and Negative Syndrome Scale (PANSS) scores. Our findings imply that mode of treatment i.e. the pharmacological intervention for psychosis may be the determining factor in weight change after diagnosis, rather than predisposing proteomic dynamics.

中文翻译：

---

SWATH 质谱在循环蛋白鉴定中的应用并不能预测早期精神病患者未来的体重增加

体重增加是在早期精神病中使用抗精神病药物治疗的常见结果，导致进一步的发病率和治疗依从性差。确定可以预测早期精神病患者体重变化的工具可能有助于更好的个体化治疗和依从性。最近我们表明，通过连续窗口采集所有理论碎片离子光谱 (SWATH) 质谱 (MS) 的蛋白质组学分析可以识别患有糖尿病前期的个体更有可能经历与生活方式改变相关的体重变化。我们使用来自抗炎抗生素米诺环素与安慰剂的 BeneMin 临床试验数据调查了基线蛋白质组学特征是否可以预测体重随时间的变化。通过 SWATH 蛋白质组学在 83 人（60 名男性和 23 名女性）中确定了 844 种蛋白质的表达水平。基线蛋白质组学数据的分层聚类分析和主成分分析没有揭示不同体重变化类别的参与者的蛋白质组谱之间的明显分离。然而，体重减轻最多的人的阳性和阴性症状量表（PANSS）得分更高。我们的研究结果表明，治疗模式，即对精神病的药物干预可能是诊断后体重变化的决定因素，而不是蛋白质组动力学的易感因素。